Skip to main content

Dr. Hyo S. Han, MD

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
27
In the NPI registry since
2007
Medicare patients seen, 2024
85

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    FL license ME101448
  • Student in an Organized Health Care Education/Training Program

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
85
Services billed
223
Patients’ average age
68
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes10951
Established patient office or other outpatient visit, 30-39 minutes5547
New patient office or other outpatient visit, 60-74 minutes2121

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Anastrozole
Other prescribers in Tampa, FL
73
Letrozole
Other prescribers in Tampa, FL
55
Ibrance (palbociclib)34
Exemestane24
Truqap (capivasertib)23
Verzenio (abemaciclib)22
Tamoxifen Citrate
Other prescribers in Tampa, FL
12
Ondansetron Hcl
Other prescribers in Tampa, FL
11

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 5 companies reported 12 payments worth $5,085 in total to this clinician.

By company
Novartis Pharmaceuticals Corporation$2,347
Pfizer Inc.$2,268
Lilly USA, LLC$229
Stemline Therapeutics Inc.$154
Gilead Sciences, Inc.$86.17
By type
Consulting Fee$4,305
Food and Beverage$780

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Mar 7, 2025Novartis Pharmaceuticals Corporation
Mar 7, 2025
Consulting Fee
KISQALI · Oncology
$2,100
Jun 13, 2025Pfizer Inc.
Jun 13, 2025
Consulting Fee
IBRANCE · ONCOLOGY
$1,260
Jan 13, 2025Pfizer Inc.
Jan 13, 2025
Consulting Fee
PAXLOVID · INFECTIOUS DISEASES
$945

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 11 industry-funded studies in 2025, from 6 companies. The companies reported $697,950 in research payments for these studies, mostly to the institutions running them.

  • A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors
    Exelixis Inc.
  • Tactiveu an interventional safety and efficacy phase 1B2 openlabel umbrella study to investigate tolerability pk and antitumor activity of ARV471 PF07850327 an oral proteolysis targeting chimera in combination with ot…
    Pfizer Inc.
  • A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun)
    Genentech, Inc.
  • I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
    Jazz Pharmaceuticals Inc.
  • Tactiveu an interventional safety and efficacy phase 1B2 openlabel umbrella study to investigate tolerability pk and antitumor activity of ARV471 PF07850327 an oral proteolysis targeting chimera in combination with ot…
    Pfizer Inc.
  • Single arm open label phase 1B2 study of SGNLIV1A in combination with pembrolizumab for firstline treatment of patients with unresectable locallyadvanced or metastatic triplenegative breast cancer
    Pfizer Inc.
  • I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
    Regeneron Pharmaceuticals, Inc. · Recruiting · NCT01042379
  • PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial
    Jazz Pharmaceuticals Inc.
  • Tactiveu an interventional safety and efficacy phase 1B2 openlabel umbrella study to investigate tolerability pk and antitumor activity of vepdegestrant ARV471PF07850327 an oral proteolysis targeting chimera in combin…
    Pfizer Inc.
  • Randomized doubleblind phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine TDM1 for subjects with unresectable locallyadvanced or metastatic HER2 breast cancer HER2CLIMB02
    Pfizer Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Tampa

Sources

NPI registry (CMS NPPES, November 2026; record last updated June 15, 2026), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1306055348. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.